These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 24738666)

  • 21. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?
    Downing NS
    JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 23. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 24. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 26. A brief history of generic substitution in the USA.
    Sullivan CG
    Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
    [No Abstract]   [Full Text] [Related]  

  • 27. An ethical dilemma. Patents & profits v. access & affordability.
    Blasi AE
    J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710
    [No Abstract]   [Full Text] [Related]  

  • 28. Indian company seeks US approval for generic AIDS drugs.
    Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 30. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 31. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 32. The Impact of Off-Patent Drug Acquisitions on Prices.
    Gupta R; Henkel A; Forman HP; Ross JS
    J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
    [No Abstract]   [Full Text] [Related]  

  • 33. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
    Engelberg AB
    Spec Law Dig Health Care Law; 2000 Sep; (258):9-48. PubMed ID: 11184791
    [No Abstract]   [Full Text] [Related]  

  • 34. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 35. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 36. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges.
    Kay M
    BMJ; 2013 May; 346():f3536. PubMed ID: 23723460
    [No Abstract]   [Full Text] [Related]  

  • 37. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 38. Improving the PPI sample for prescription pharmaceuticals.
    Kelly GG
    Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
    [No Abstract]   [Full Text] [Related]  

  • 39. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 40. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH
    Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.